183 related articles for article (PubMed ID: 23418396)
1. Phosphorylation of threonine 333 regulates trafficking of the human sst5 somatostatin receptor.
Petrich A; Mann A; Kliewer A; Nagel F; Strigli A; Märtens JC; Pöll F; Schulz S
Mol Endocrinol; 2013 Apr; 27(4):671-82. PubMed ID: 23418396
[TBL] [Abstract][Full Text] [Related]
2. Identification of Phosphorylation Sites Regulating sst3 Somatostatin Receptor Trafficking.
Lehmann A; Kliewer A; Günther T; Nagel F; Schulz S
Mol Endocrinol; 2016 Jun; 30(6):645-59. PubMed ID: 27101376
[TBL] [Abstract][Full Text] [Related]
3. Carboxyl-terminal receptor domains control the differential dephosphorylation of somatostatin receptors by protein phosphatase 1 isoforms.
Lehmann A; Kliewer A; Märtens JC; Nagel F; Schulz S
PLoS One; 2014; 9(3):e91526. PubMed ID: 24637622
[TBL] [Abstract][Full Text] [Related]
4. Carboxyl-terminal multi-site phosphorylation regulates internalization and desensitization of the human sst2 somatostatin receptor.
Lehmann A; Kliewer A; Schütz D; Nagel F; Stumm R; Schulz S
Mol Cell Endocrinol; 2014 Apr; 387(1-2):44-51. PubMed ID: 24565897
[TBL] [Abstract][Full Text] [Related]
5. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
Lesche S; Lehmann D; Nagel F; Schmid HA; Schulz S
J Clin Endocrinol Metab; 2009 Feb; 94(2):654-61. PubMed ID: 19001514
[TBL] [Abstract][Full Text] [Related]
7. Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5.
Schulz S; Lehmann A; Kliewer A; Nagel F
Br J Pharmacol; 2014 Apr; 171(7):1591-9. PubMed ID: 24328848
[TBL] [Abstract][Full Text] [Related]
8. Structural determinants of agonist-selective signaling at the sst(2A) somatostatin receptor.
Nagel F; Doll C; Pöll F; Kliewer A; Schröder H; Schulz S
Mol Endocrinol; 2011 May; 25(5):859-66. PubMed ID: 21330405
[TBL] [Abstract][Full Text] [Related]
9. Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists.
Kao YJ; Ghosh M; Schonbrunn A
Mol Endocrinol; 2011 Jun; 25(6):1040-54. PubMed ID: 21493671
[TBL] [Abstract][Full Text] [Related]
10. Rapid dephosphorylation of G protein-coupled receptors by protein phosphatase 1β is required for termination of β-arrestin-dependent signaling.
Pöll F; Doll C; Schulz S
J Biol Chem; 2011 Sep; 286(38):32931-6. PubMed ID: 21795688
[TBL] [Abstract][Full Text] [Related]
11. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
[TBL] [Abstract][Full Text] [Related]
12. Intracerebroventricular injection of somatostatin sst5 receptor agonist inhibits gastric acid secretion in rats.
Martínez V; Coy DH; Lloyd KC; Taché Y
Eur J Pharmacol; 1996 Jan; 296(2):153-60. PubMed ID: 8838451
[TBL] [Abstract][Full Text] [Related]
13. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.
Pöll F; Lehmann D; Illing S; Ginj M; Jacobs S; Lupp A; Stumm R; Schulz S
Mol Endocrinol; 2010 Feb; 24(2):436-46. PubMed ID: 20051480
[TBL] [Abstract][Full Text] [Related]
14. [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Siehler S; Seuwen K; Hoyer D
Eur J Pharmacol; 1998 May; 348(2-3):311-20. PubMed ID: 9652348
[TBL] [Abstract][Full Text] [Related]
15. Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST
Treppiedi D; Marra G; Di Muro G; Catalano R; Mangili F; Esposito E; Calebiro D; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2022; 13():892668. PubMed ID: 35992099
[TBL] [Abstract][Full Text] [Related]
16. Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.
Ben-Shlomo A; Pichurin O; Barshop NJ; Wawrowsky KA; Taylor J; Culler MD; Chesnokova V; Liu NA; Melmed S
Mol Endocrinol; 2007 Oct; 21(10):2565-78. PubMed ID: 17609435
[TBL] [Abstract][Full Text] [Related]
17. A transplantable phosphorylation probe for direct assessment of G protein-coupled receptor activation.
Kliewer A; Mann A; Petrich A; Pöll F; Schulz S
PLoS One; 2012; 7(6):e39458. PubMed ID: 22745760
[TBL] [Abstract][Full Text] [Related]
18. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a New
Mansi R; Nicolas GP; Del Pozzo L; Abid KA; Grouzmann E; Fani M
Molecules; 2020 Sep; 25(18):. PubMed ID: 32932783
[TBL] [Abstract][Full Text] [Related]
20. The PDZ Domain Protein SYNJ2BP Regulates GRK-Dependent Sst2A Phosphorylation and Downstream MAPK Signaling.
Carr HS; Chang JT; Frost JA
Endocrinology; 2021 Feb; 162(2):. PubMed ID: 33313679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
